Long Non-Coding RNA PCED1B-AS1 Promotes the Progression of Clear Cell Renal Cell Carcinoma Through miR-484/ZEB1 Axis

Background: Long non-coding RNA (lncRNA) has been recognized as the new regulator and biomarker for cancers. However, in clear cell renal cell carcinoma (ccRCC), the functions of lncRNAs are not well characterized. This research aimed to probe the function of lncRNA PCED1B-AS1 in the progression of ccRCC.

Materials and Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to detect the expression levels of PCED1B-AS1, microRNA-484 (miR-484), and zinc finger E-box binding homeobox 1 (ZEB1) in 40 pairs of human ccRCC tissues and corresponding adjacent kidney tissue samples. Chi-square test was employed to evaluate the association between PCED1B-AS1 expression level and clinicopathological characteristics. The effects of PCED1B-AS1, miR-484 and ZEB1 on the cell proliferation, migration and epithelial-mesenchymal transition (EMT) process of ccRCC cells were studied by CCK-8 assay, EdU cell proliferation assay, wound healing test and Western blotting. The regulatory relationships among PCED1B-AS1, miR-484, ZEB1 were examined by luciferase reporter gene assay and RNA immunoprecipitation assay.

Results: PCED1B-AS1 was remarkably up-regulated in ccRCC tissues and cell lines. High expression of PCED1B-AS1 was associated with poor prognosis of the patients. Loss-of-function experiments showed that PCED1B-AS1 could regulate the proliferation, migration and EMT of ccRCC cells. PCED1B-AS1 sponged miR-484 to suppress its expression, and miR-484 targeted the 3′-UTR of ZEB1 to repress the expression of ZEB1. MiR-484 counter-acted the functions of PCED1B-AS1 in promoting the proliferation, migration and EMT of ccRCC cells, and PCED1B-AS1 promotes the expression of ZEB1 via repressing miR-484.

Conclusion: PCED1B-AS1/miR-484/ZEB1 axis is involved in regulating the progression of ccRCC.

Keywords: ccRCC, PCED1B-AS1, miR-484, ZEB1

Introduction

Renal cell carcinoma (RCC) is the second most common cause of death in patients with urinary tumors, which has a high mortality worldwide.1 In 2015, there are about 66.8 thousands of new RCC cases in China, and clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, taking up about 75% of all cases.2,3 Although the treatment of ccRCC has been improved, the prognosis is still very poor due to its high rate of metastasis and recurrence, and the median survival time of the patients is only about 1.5 years.4 In addition, ccRCC cells are less sensitive to conventional chemotherapy and radiotherapy. Hence, an in-depth...
understanding of the molecular regulatory mechanisms in the occurrence and development of ccRCC will help develop novel treatment strategy for ccRCC.

Accumulating studies have shown that long non-coding RNA (lncRNA) is implicated in a variety of biological processes, such as cell proliferation, cell cycle, cell differentiation, and apoptosis.\(^6\)\(^-\)\(^8\) LncRNA dysregulation has been found to be associated with the carcinogenesis and development of ccRCC.\(^9\)\(^-\)\(^11\) For example, high expression of lncRNA PANDAR is related to high TNM stage, lymph node metastasis and distant metastasis of ccRCC patients, and silencing of PANDAR induces cell cycle arrest and apoptosis of ccRCC cells.\(^10\) LncRNA TP73-AS1 promotes viability and inhibits apoptosis of ccRCC cells via interacting with EZH2 and repressing the PI3K/Akt/mTOR pathway to suppress the expression of KISS1.\(^11\) PC-esterase domain containing 1B antisense RNA 1 (PCED1B-AS1) is a rarely studied lncRNA, and its role and mechanism in ccRCC are unclear.

MicroRNA (miRNA) can down-regulate target gene expression by binding to the 3’-untranslated region (3’-UTR), playing a prominent role in regulating diverse biological processes.\(^12\) Aberrantly expressed miRNAs participate in the growth and metastasis of ccRCC.\(^13\)\(^-\)\(^16\) For example, miR-663 is down-regulated in ccRCC tissues and cell lines, and miR-663 can directly target PAK4 to impede the proliferation and invasion of ccRCC cells.\(^15\) Additionally, in ccRCC, miR-124 and miR-203 participate in the activation of the epithelial-mesenchymal transition (EMT) pathway by regulating ZEB2.\(^16\) Accumulating studies show that lncRNA can function as a competitive endogenous RNA (ceRNA) to regulate downstream gene expression at the post-transcriptional level by sponging miRNAs.\(^17\) For example, lncRNA SNHG12 regulates MDM4 expression and the p53 pathway during the development of ccRCC by acting as a ceRNA for miR-125-5p.\(^18\)

In the research, we demonstrated that PCED1B-AS1 was up-regulated in ccRCC tissues, and PCED1B-AS1 expression was related to clinical stage and Fuhrman grade of ccRCC. It was further found that silencing of PCED1B-AS1 suppressed the proliferation, migration and epithelial-mesenchymal transition (EMT) of ccRCC cells. Additionally, it was revealed that, functioning as a ceRNA, PCED1B-AS1 directly targeted miR-484 to increase the expression of zinc finger E-box binding homeobox 1 (ZEB1) to promote ccRCC progression.

**Materials and Methods**

**Sample Collection**

The study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University (Approval Number: 201,708,042). All samples were available from patients undergoing radical or partial nephrectomy in the Affiliated Hospital of Southwest Medical University. A total of 40 pairs of ccRCC samples and matching normal kidney tissue samples were obtained. All samples were confirmed by postoperative pathological examination. All tissues were frozen and stored in liquid nitrogen until RNA extraction. The clinicopathological characteristics of these patients were recorded, and each patient provided written informed consent.

**Cell Culture and Transfection**

Human ccRCC cell lines (786-O, A498, ACHN, and Caki-1) and immortalized normal human renal tubular epithelial cell line (HK-2) were procured from the Institute of Cell Research, Chinese Academy of Sciences (Shanghai, China). A498, 786-O, and HK-2 cells were cultured in RPMI-460 medium (HyClone, Logan, UT, USA). ACHN cells were cultured in DMEM (Invitrogen, Waltham, MA, USA), and Caki-1 cells were cultured in McCoy’s 5A medium (Gibco, Los Angeles, CA, USA). All medium contained 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA), and the cells were placed in an incubator at 37 °C and in 5% CO\(_2\).

siRNA specifically targeting PCED1B-AS1 (si-PCED1BAS1) and siRNA negative control (si-NC), as well as miR-484 mimics, NC mimics, miR-484 inhibitors and NC inhibitors were provided by GenePharma (Shanghai, China). In accordance with the manufacturer’s instruction, they were transfected into A498 and Caki-1 cells using Lipofectamine™ 3000 Reagent (Invitrogen, Carlsbad, CA, USA).

**Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)**

Total RNA was extracted from the tissue samples and cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The total RNA was reverse transcribed into cDNA using PrimeScript RT reagent kit with gDNA Eraser (Takara, Dalian, China). For miR-484, reverse transcription was performed using the One Step PrimeScript miRNA cDNA Synthesis Kit (Takara, Dalian, China). qRT-PCR was carried out on an ABI 7500 Real-Time PCR System (Applied
ZEB1

OncoT

y

484

y

W

Cell

CAGGGTCCGAGGT

TGCGGGTGCTCGCTTCGGCAGC-3ʹ

drogenase

TGCCG-3ʹ

dakara,

TGTTGGCCAA

GAPDH

TGA

AGC-3ʹ;

TGACCACAGTCCA

Dove

30

EdU

EdU

a

ture

30

EdU

37

°C

Dalian,

China).

48, 72 and 96 h, 10 µL of cell counting kit-8 (CCK-8) solution (Dojindo, Kumamoto, Japan) was supplemented to each well, respectively, and incubated at 37 °C for 2 h. Then, the optical density of the cells was measured at 450nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA).

The EdU proliferation detection kit (Beyotime, Shanghai, China) was also employed to monitor the proliferation of ccRCC cells. Briefly, after 2 h of incubation with EdU kit, the cells were fixed with 4% paraformaldehyde for 30 min. After performing Apollo staining at room temperature for 30 min, DAPI staining solution was added and the cells were incubated at room temperature for 20 min in the dark. After the cells were washed with PBS, EdU-positive cells were observed, photographed and counted under a fluorescence microscope (Olympus, Tokyo, Japan).

Wound Healing Assay

Cell migration was assessed by wound healing experiment. In short, when the cells covered the bottom of the well, the cells were scratched with a sterile 200 µL pipette tip. After washing, the cells were cultured in a serum-free medium. After 0 and 24 h of culture, the images of the scratches were collected under a microscope (Olympus, Tokyo, Japan), respectively, and the width of the wound was measured.

Dual-Luciferase Reporter Gene Assay

HEK-293 cells were inoculated into 24-well plates, and miR-484 mimics or NC mimics and pmirGLO plasmids containing wild-type or mutant sequence of PCED1B-AS1 or 3’-UTR of ZEB1 were co-transfected into HEK-293 cells by Lipofectamine™ 3000 reagent (Invitrogen, Carlsbad, CA, USA). Forty-eight hours later, the luciferase activity of the cells in each group was determined by Dual-Luciferase® Reporter Assay System (Promega, Beijing, China). The firefly luciferase activity was normalized by renilla luciferase activity.

RNA Immunoprecipitation (RIP)

The binding relationship between PCED1B-AS1 and miR-484 was detected using a Magna RIP RNA-binding protein immunoprecipitation kit (Millipore, Bedford, MA, USA). The ccRCC cells were lysed with RIP buffer. Cell extracts were then incubated with magnetic beads, which were coupled with anti-Ago2 antibody or control IgG (Millipore, Billerica, MA, USA). Subsequently, the immunoprecipitate was incubated with proteinase K (Sigma-Aldrich, Louis, MO, USA), and total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and ultimately, the enrichment of PCED1B-AS1 and miR-484 was detected by qRT-PCR.

Western Blotting

Protein was extracted from cells with RIPA buffer (Beyotime, Shanghai, China), and the total protein was separated on 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA). The membrane was then blocked with 5% skimmed milk, and the membrane was incubated with the primary antibody at 4 °C overnight. Thereafter, the membrane was incubated with the secondary antibody for 1 h at room temperature. β-Actin was used as the endogenous control, and the protein bands were exposed with enhanced chemiluminescence kit (Millipore, Billerica, MA, USA). The information of primary antibody is as follows: anti-ZEB1 (1:1000, Abcam, ab203829), anti-N-cadherin (1:1000, Abcam, ab202030), anti-E-cadherin (1:1000, Abcam, ab40772), and anti-β-actin (1:2000, Abcam, Ab8226). All of the primary antibodies were obtained from Abcam (Cambridge, UK). The secondary antibodies were obtained from Beyotime (Shanghai, China).

Statistical Analysis

SPSS 20.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 8 software (GraphPad Software Inc., San Diego, CA, USA) were used for statistical analysis and graphing. Each experiment was repeated for at least three times, and all data were expressed as mean ± standard deviation. Data were analyzed using one-way ANOVA or Student’s t-test. Pearson’s correlation coefficient was employed to analyze the correlations among PCED1B-AS1, miR-484 and ZEB1. P < 0.05 indicated statistical significance.
Results

PCED1B-AS1 Was Up-Regulated in ccRCC Tissues and Cell Lines and Was Associated with Adverse Prognosis

To explore the expression characteristics and prognostic value of PCED1B-AS1 in ccRCC, we first analyzed the data in the GEPIA database. The results showed that compared with normal tissues, PCED1B-AS1 was highly expressed in ccRCC (KIRC) and renal papillary cell carcinoma (KIRP), but not changed in kidney chromophobe (KICH) (Figure 1A). The overall survival time (OS) of ccRCC patients with high expression of PCED1B-AS1 was significantly shorter than those with low expression of PCED1B-AS1 (Figure 1B). We also measured the expression level of PCED1B-AS1 in ccRCC tissues and cell lines using qRT-PCR, and the results revealed that the expression level of PCED1B-AS1 in ccRCC tissues was remarkably higher than normal kidney tissue (Figure 1C). Additionally, the expression levels of PCED1B-AS1 in 786-O, A498, ACHN, and Caki-1 cell lines were also remarkably up-regulated compared with HK-2 cells (Figure 1D). What is more, we further analyzed the relationship between PCED1B-AS1 expression and the clinicopathological characteristics of ccRCC patients (Table 1). ccRCC patients were divided into low expression group (n=20) and high expression group (n=20). The results showed that high expression of PCED1B-AS1 was associated with high tumor stage and high Fuhrman grade, but not related to age, gender, tumor diameter, and lymph node metastasis. The data indicated that PCED1B-AS1 may play a tumor-promoting role in ccRCC.

PCED1B-AS1 Promoted the Proliferation and Migration of ccRCC Cells

To probe the function of PCED1B-AS1 in ccRCC, we investigated its biological function in A498 and Caki-1 cells by knocking down PCED1B-AS1 expression using siRNA (Figure 2A). We measured cell proliferation using CCK-8 and EdU assays. The results showed that PCED1B-AS1 knockdown markedly suppressed the proliferation of A498 and Caki-1 cells (Figure 2B and C). Wound healing experiments were used to examine the effect of PCED1B-AS1 on cell migration, the results of which demonstrated that the migration ccRCC cells with
PCED1B-AS1 silenced was significantly inhibited (Figure 2D). Western blotting was used to detect the expression of EMT-related proteins, and the data demonstrated that silencing of PCED1B-AS1 significantly increased E-cadherin expression and decreased N-cadherin expression in ccRCC cells (Figure 2E).

**Table 1** Correlation Between PCED1B-AS1 Expression and Clinicopathologic Features of ccRCC Patients

<table>
<thead>
<tr>
<th>Factors</th>
<th>Total (n=40)</th>
<th>Expression of PCED1B-AS1</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Diagnosis age (years)</td>
<td>≤60</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>&gt;60</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Tumor stage</td>
<td>pT1</td>
<td>16</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>pT2/T3</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>Fuhrman grade</td>
<td>I+II</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>III+IV</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>Tumor diameter (cm)</td>
<td>≤7 cm</td>
<td>8</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>&gt;7 cm</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>Negative</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>5</td>
<td>9</td>
</tr>
</tbody>
</table>

**Note:** *P*<0.05 (chi-square test).

The results of cytoplasmic/nuclear separation experiments showed that PCED1B-AS1 was mainly expressed in the cytoplasm of A498 and Caki-1 cells, suggesting it could probably function as a ceRNA (Figure 3A). Next, we performed bioinformatics predictions on the DIANA database, and it was predicted that PCED1B-AS1 sequence that could potentially bind with miR-484 (Figure 3B, Supplementary Table 1). To verify the targeting relationship between them, we co-transfected PCED1B-AS1-WT luciferase reporter vector or PCED1B-AS1-MUT luciferase reporter vector and miR-484 mimics or NC mimics into A498 and Caki-1 cells. The results revealed that the luciferase activity in PCED1B-AS1-WT group was remarkably inhibited after transfection with miR-484 mimics, while the luciferase activity in PCED1B-AS1-MUT-transfected cells remained unchanged (Figure 3C). Additionally, RIP analysis showed that anti-Ago2 antibodies were able to immunoprecipitate PCED1B-AS1 and miR-484 in both A498 and Caki-1 cell lysates (Figure 3D). Moreover, qRT-PCR found that miR-484 was markedly down-regulated in ccRCC tissues compared with normal kidney tissues (Figure 3E), and Pearson’s correlation analysis indicated that there was a negative correlation between PCED1B-AS1 expression and miR-484 expression in ccRCC tissues (Figure 3F). Additionally, compared with HK-2 cells, miR-484 expression in ccRCC cells was down-regulated (Figure 3G). These data suggested that PCED1B-AS1 could sponge miR-484 and inhibit its expression in ccRCC.

**miR-484 Played a Tumor-Suppressive Role in ccRCC**

We further explore the role of miR-484 in ccRCC. We transfected miR-484 mimics or NC mimics into A498 and Caki-1 cells, and as shown, miR-484 expression in the cells transfected with miR-484 mimics was remarkably increased (Figure 4A). Moreover, CCK-8 and EdU assays showed miR-484 overexpression repressed the proliferation of ccRCC cells (Figure 4B and C). Wound healing assay indicated that miR-484 overexpression blocked the migration of ccRCC cells (Figure 4D). Western blotting revealed that compared with the control group, E-cadherin was increased and N-cadherin was decreased in the ccRCC cells in the miR-484 overexpression group (Figure 4E). These results indicated that miR-484 had an inhibitory effect on the progression of ccRCC.

**ZEB1 Was a Direct Target Gene of miR-484**

Furthermore, TargetScan database predicted that ZEB1 was a candidate target of miR-484 (Figure 5A). The dual-luciferase reporter experiment revealed that transfection of miR-484 mimics reduced luciferase activity of ZEB1-WT reporter, but had no significant effect on the luciferase activity in ZEB1-MUT group (Figure 5B). Western blotting indicated that ZEB1 protein expression was markedly inhibited in miR-484 mimics-transfected cells (Figure 5C). In addition, we found that ZEB1 expression was remarkably higher in ccRCC tissues.

**PCED1B-AS1 Acted as ceRNA of miR-484 in ccRCC**

OncoTargets and Therapy 2021:14

submit your manuscript | www.dovepress.com
DovePress

397

Dovepress

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 29 Aug 2021
For personal use only.
than in normal kidney tissues (Figure 5D), and correlation analysis showed that ZEB1 was positively correlated with PCED1B-AS1 expression (Figure 5E). The data indicated that ZEB1 was a direct target of miR-484 in ccRCC cells, and could probably be regulated by PCED1B-AS1.

**PCED1B-AS1 Played a Carcinogenic Role in ccRCC Cells Through Regulating miR-484/ZEB1 Axis**

To elucidate whether PCED1B-AS1 modulated cell proliferation, migration, and EMT through miR-484/ZEB1 axis,
we co-transfected miR-484 inhibitors into A498 and Caki-1 cells with PCED1B-AS1 silenced, and then “rescue” experiments were performed. qRT-PCR revealed that silencing PCED1B-AS1 increased the expression of miR-484, and the transfection of miR-484 inhibitors remarkably inhibited miR-484 expression (Figure 6A). Western blotting revealed that inhibiting PCED1B-AS1 significantly inhibited the expression of ZEB1, and transfection of miR-484 inhibitors partially restored ZEB1 protein expression (Figure 6B). Functional experiments showed that inhibition of miR-484 counteracted the effects of PCED1B-AS1 knockdown on the proliferation, migration,
and EMT of A498 and Caki-1 cells (Figure 6C–F). Briefly, these data indicated that PCED1B-AS1 played a promoting role in the ccRCC progression through regulating the miR-484/ZEB1 axis.

**Discussion**

ccRCC is one of the most common genitourinary cancers around the world. ccRCC patients have limited treatment options, high recurrence rates, and unfavorable prognosis. Therefore, studying the mechanism of ccRCC carcinogenesis and progression and finding potential molecular biomarkers and therapeutic targets are of great significance. Accumulating studies have found that lncRNA plays a key role in the carcinogenesis and development of ccRCC.\(^8\)\(^,\)\(^19\) For instance, it is reported that lncRNA CRNDE is over-expressed in ccRCC tissues and cell lines, and in vitro functional experiments indicate that CRNDE can enhance the migration and invasion of ccRCC cells.\(^20\) Another study reports that lncRNA SNHG5 is up-regulated in ccRCC tissues, and inhibition of SNHG5 reduces the proliferation and invasion of ccRCC cell and promoted apoptosis.\(^21\)

Nonetheless, the functions and molecular mechanisms of lncRNA in ccRCC progression have not been fully clarified. PCED1B-AS1 is a rarely studied lncRNA. It is reported that lncRNA PCED1B-AS1 is up-regulated in luminal B breast cancer and glioblastoma tissues; PCED1B-AS1 can bind to the 5′-UTR of HIF-1α mRNA and facilitates HIF-1α translation, thereby promoting the Warburg effect and tumorgenesis of glioblastoma.\(^22\)\(^,\)\(^23\) In addition, PCED1B-AS1 can modulate the miR-194-5p/PCED1B axis to promote glioma cell proliferation and inhibit apoptosis.\(^24\) In the current research, for the first time, we investigated the expression and biological function of PCED1B-AS1 in ccRCC. We found that PCED1B-AS1 was up-regulated in ccRCC, and the knockdown of PCED1B-AS1 inhibited cell proliferation, migration, and EMT process, indicating that PCED1B-AS1 functioned as a cancer-promoting factor in ccRCC.
Recent researches show that lncRNAs target miRNAs as ceRNAs to participate in tumorigenesis and cancer progression.\textsuperscript{25} For example, lncRNA SBF2-AS1 promotes cervical cancer progression by sponging and repressing miR-361-5p to up-regulate FOXM1.\textsuperscript{26} LncRNA HOTAIR regulates the growth, metastasis, and apoptosis of breast cancer cells through the miR-20a-5p/HMGAA2 axis.\textsuperscript{27} In previous studies, miR-484 has been proved to be a tumor suppressor in several cancers, such as cervical cancer and gastric cancer.\textsuperscript{28,29} In this study, we found that PCED1B-AS1 can function as ceRNA for miR-484 to inhibit its expression. What is more, miR-484 overexpression inhibited the proliferation and migration of ccRCC cells and EMT process. Our data suggested that miR-484 was a tumor suppressor in ccRCC, and PCED1B-AS1 could negatively regulate its expression.

ZEB1 is a crucial regulatory element of the transcription factor network and mainly controls the EMT process.\textsuperscript{30,31} ZEB1 is abnormally expressed in a variety of cancers, such as colorectal cancer, lung cancer, breast cancer, and gastric cancer, and it is involved in the proliferation, migration and invasion of cancer cells and is considered to have cancer-promoting functions.\textsuperscript{32–36} For example, lncRNA TMPO-AS1 facilitates the proliferation, migration, and invasion of cervical cancer cells by modulating the miR-143-3p/ZEB1 axis.\textsuperscript{37} In this study, we predicted and verified that miR-484 was able to target ZEB1, and that ZEB1 expression in ccRCC patient tissues was positively regulated by PCED1B-AS1. “Rescue” experiments showed that transfection with miR-484 inhibitor not only partially restored ZEB1 expression but also significantly weakened the inhibition of PCED1B-AS1 knockdown on ccRCC cell proliferation, migration, and EMT process. Therefore, these findings suggested that PCED1B-AS1 could regulate the occurrence and development of ccRCC by regulating the miR-484/ZEB1 axis.

In summary, we demonstrate the up-regulation of PCED1B-AS1 in ccRCC and reveal that PCED1B-AS1 enhances ccRCC cell proliferation, migration, and EMT process. Additionally, PCED1B-AS1 positively regulated ZEB1 expression through sponging and repressing miR-484. These findings are helpful to further understand the carcinogenesis and development mechanism of ccRCC, providing a possible direction for the therapy of ccRCC. Notably, PCED1B-AS1 can probably target multiple miRNAs besides miR-484, which may be involved in the regulation of multiple signal pathways. In the future research, a more comprehensive study of the function and mechanism of PCED1B-AS1 in ccRCC is needed.

**Ethics Statement**

The study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University (Number: 201,708,042), and each patient provided informed consent.

**Funding**

This work is supported by the National Natural Science Foundation of China (No. 81800670) and Foundation of Luzhou-Southwest Medical University (No. 2017lzxnyd-j32).

**Disclosure**

The authors report no conflicts of interest for this work.

**References**


